



**Research  
Scholars**

# Gilead and Kite's Research Scholars Program in Hematologic Malignancies

December 2022, MA-NON-NA-US-00014

GILEAD and the GILEAD Logo are trademarks of Gilead Sciences, Inc. KITE and the KITE Logo are trademarks of Kite Pharma, Inc.

All other trademarks referenced herein are the property of their respective owners. ©2022 Gilead Sciences, Inc. All rights reserved.

---

# Contents

Section	Page
<b>1</b> Research Scholars Program Overview .....	<b>3</b>
<b>2</b> Hematologic Malignancies Program Overview .....	<b>4</b>
<b>3</b> Eligibility Criteria .....	<b>5</b>
<b>4</b> Application Information .....	<b>6</b>
<b>5</b> Guidelines for the Research Proposal .....	<b>6</b>
<b>6</b> Budget Guidelines .....	<b>7</b>
<b>7</b> Scientific Review Committee .....	<b>8</b>
<b>8</b> Contact Information .....	<b>9</b>



# Research Scholars Program Overview

The Research Scholars Program supports innovative research from emerging investigators around the world to incorporate new perspectives in our pursuit of scientific understanding and progress. We believe that new voices and research topics are needed to advance scientific knowledge in areas of unmet medical need and create a healthier world.

Since 2008, Gilead's Research Scholars Program has invested more than \$31 million USD into meaningful basic, translational and clinical scientific research conducted by more than 240 scholars to help transform scientific understanding, address knowledge gaps and drive medical breakthroughs.

Each of our Research Scholars Programs is overseen by a scientific review committee comprised of distinguished experts in their respective fields who are independent from Gilead to ensure equal, objective evaluation of all applicants and their applications. This enables us to maintain the program's overall integrity and competitive standards, and to ensure awards support the next generation of breakthrough scientific discovery.

Each award is funded up to \$180,000 USD over two years, paid as annual instalments of \$90,000 USD per year directly to the scholars' institution. Funding for the second year is contingent upon submission of a progress report and approval by the chair of the scientific review committee.

## Diversity Fosters Innovation

The Research Scholars Program is actively working towards reducing potential barriers to entry and success for applicants from population groups who are typically underrepresented in research. We are committed to supporting researchers and research projects addressing unmet patient needs and health inequities in order to build a more inclusive research landscape.

Award selections are made without discrimination based on race, ethnicity, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression.



# Hematologic Malignancies Program Overview

This program is designed to support both clinical and basic research projects that addresses any unmet medical need in Hematologic Malignancies in the United States. The awards for this cycle will be divided evenly to support both clinical and basic scientific research.

Examples of areas of research could include, but are certainly not limited to:

- Health inequities and disparities in cancer care
- A broad range of adult or pediatric blood cancers
- Clinical treatment modalities (IO, cell therapy, targeted therapies etc)
- Understanding the mechanisms of patient response or resistance to treatments
- Research to improve Quality of Life (QoL) e.g. adverse events
- Research to improve Patient-Report Outcomes (PROs) e.g. addressing unmet needs for patients
- Any other basic, translational and/or clinical research that addresses an unmet medical need or a gap in scientific knowledge
- Novel diagnostic, prevention, and treatment strategies
- Patient-specific factors that are predictors of toxicity
- Transformative therapeutic modalities/approaches to treatment
- Agnostic approaches to Hematologic Malignancies



**The Hematologic Malignancies program provides a minimum of 4 awards**

## Program Timeline

**Application Deadline:** April 14, 2023, 11:59 PM, Pacific Standard Time

“

**The Gilead Research Scholars program allowed me to fund critical research at an early stage of my independent career, which I could not have done without the award.**

”

– Dr. Daniel Hodson





# Eligibility Criteria

The Research Scholars Program in Hematologic Malignancies is open to emerging investigators from the United States.

## Applicants must meet the following requirements:

- Hold an MD, PhD, or equivalent degree at time of award and be associated with a research institution in the United States
- For clinical science applicants, you should be within 7 years of completion of speciality training (e.g. medical oncology, radiation oncology, surgical oncology, paediatric oncology, or equivalent)
- For non-clinical applicants, you should be within 7 years of your initial faculty appointment
- Applicants who hold positions that are more senior than Assistant Professor level (or equivalent) at the time of application are not eligible
- Have a research mentor with extensive experience in the field of hematology/oncology (co-mentorship is permissible)
- Be able to devote approximately 30% or more of professional time to research for the next 2 years (versus administrative, patient care, or teaching responsibilities)
- Be able to complete the proposed research within the 2-year award period, providing evidence (manuscript, presentation, or abstracts) resulting from the research

**The Research Scholars Program is actively working towards reducing potential barriers to entry and success for applicants from population groups who are typically underrepresented in research. Award selections are made without discrimination based on race, ethnicity, religion, national origin, gender, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression.**

## Citizenship

An applicant must be a citizen or permanent resident of the United States or subject to the qualifications noted below hold a temporary non-immigrant visa/work permit. This visa must be valid and must allow the applicant to undertake the research over the two-year award period from the United States. This non-immigrant visa/work permit must be valid for the two-year award period or applicant must be able to establish that he or she is eligible for an extension, renewal or other status that will enable the applicant to perform the research in the applicable jurisdiction for the entirety of the two-year award period.

“

**The Gilead Research Scholars Program award provided additional support and funding to really make my research more innovative.**

”

– Dr. Kristine Mace Erlandson



# Application Information

Applications must be completed online via the [program portal](#) and submitted electronically with the required supplementary materials.

Applications are reviewed and selected by an independent Scientific Review Committee comprised of internationally recognized experts in clinical and basic research in the field of Hematologic Malignancies.

Gilead Sciences is not involved in the review and/or selection of awardees in order to maintain the scientific integrity and independence of the program.

Proposals utilizing Gilead and Kite product(s) are not eligible for funding through the Research Scholars Program. Proposals involving Gilead product(s) should be submitted for review under the Investigator-Sponsored Research Grant Program through the [ISR online portal](#).

All applications are initially reviewed by three Scientific Review Committee members as part of a triage and are marked as competitive vs. non-competitive.

Each competitive application is then further reviewed by two Scientific Review Committee members based on the criteria listed below.

The highest scoring applications will then be discussed at length by all Scientific Review Committee members at a review meeting. The awardees and runners up are then selected by consensus of the committee.

## The committee will consider the following criteria when evaluating applications:

### 1. Evaluation of the applicant

- Potential for a career in hematology/oncology-related research
- Academic record (presentations, publications etc)
- Prior research experience and/or publications focused on Hematologic Malignancies

### 2. Evaluation of the Mentor Support and Mentoring Plan

A mentor is someone who makes a commitment to your research career. They should be responsible for guiding not only your research proposal but also your application for funding and help you with your professional development and advancement.


As mentorship can come from different people for different aspects of your research career, we do allow co-mentorship although ask that one of your mentors be located within your institution

- Letter of support from mentor(s) which includes: mentor's track record of productivity, funding, and success with prior trainees; detailed description of the mentoring plan, including resources allocated to the proposed research project, provision of protected time, and available laboratory facilities (if relevant)
- The mentor(s) is an independent investigator
- The mentor(s) has the experience to direct the proposed research training, as evidenced by the letter of support
- The mentoring training plan and mentor-mentee relationship is sufficient to facilitate the applicant's progress towards their research career goals
- Letter of support from the department chair or division chief to document the institution is willing, and has the ability, to commit the resources necessary for the applicant to complete the proposed research, including sufficient protected time

**It's important that your mentor reviews your research proposal and associated documentation before submission to ensure it is at the highest standard and submitted error free.**

### 3. Evaluation of the proposal

- **Innovation and Significance:** The research proposal is new and original and addresses an important question/issue related to Hematologic Malignancies. The proposed study will have an effect on concepts, methods, and/or technologies related to Hematologic Malignancies research.
- **Approach:** The conceptual framework, design, methods, and analyses are adequately developed, well-integrated, well-reasoned, feasible (as determined by preliminary data or the expertise available), and appropriate to the aims of the project. The applicant acknowledges potential problem areas and considers alternative tactics.
- **Feasibility:** The project, as described in the submitted proposal and budget, can be accomplished within the timeframe of the award.





# Budget Guidelines

Each selected Awardee is funded up to \$180,000 USD (inclusive of any indirect costs), to be paid in two annual installments of up to \$90,000 USD per year directly to the researcher's institution. Funding for the second year is contingent upon submission of a progress report by each junior faculty researcher and approval by the Chair of the Scientific Review Committee.

An itemized budget must be submitted with the proposal, consistent with the following guidelines:

## Indirect Costs

To maximize the research benefit of the award, the program encourages that every effort be made to minimize the utilization of the award to cover indirect costs. Indirect costs may not exceed 10% of the award value, and are included as part of the budget, not as an addition to the value of the award (subject to local variances to be approved by Gilead Sciences).

Indirect costs are defined as overhead costs paid directly to the institution, for example maintenance of labs/space and departmental/admin costs.

## Salaries

The applicant may allocate up to \$75,000 USD per year in salary and fringe benefits support for the applicant and/or a technician.

Salaries and fringe benefits for mentors or students may not be included.

## Supplies

Supplies such as disposables, chemicals, reagent kits, animals, etc, may be included.

Purchases of durable equipment with a single item value of greater than \$2,500 is not permitted within the budgets, however, the budget can support rental/lease of this durable equipment.

- Durable equipment would be lab tools and devices that are designed for use over a long period of time (e.g. many years), being resistant to wear and generally would be items that can be rented.
- Durable equipment excludes lab supplies and similar single-use or disposable products.

## Travel

Up to \$1,500 USD per year for applicant's travel to a scientific meeting for presentation of data may be included.

The above are guidelines only and can be addressed on a case by case basis if necessary for the research.

*If the research project includes investigations on human subjects, a copy of the submission to the Institutional Review Board (IRB) must be submitted prior to award. Award will be contingent upon IRB approval.*

*If the research project involves laboratory animals, researcher must certify that he/she will comply with all laws and regulations pertaining to care and use of animals in research prior to award.*



---

## Scientific Review Committee

---

Applications will be reviewed by the Committee, comprised of internationally recognized experts in clinical and basic research in the field of Hematologic Malignancies:

### Chair



**Jorge Cortes, MD**  
**Director, Georgia Cancer Center**  
Georgia Cancer Center at Augusta University  
Augusta, GA

### Committee



**Loretta J. Nastoupil, MD**  
**Associate Professor, Department of Lymphoma-Myeloma**  
Division of Cancer Medicine  
University of Texas MD Anderson Cancer Center  
Houston, TX



**Olalekan O. Oluwole, MD, MPH, MBBS**  
**Associate Professor of Medicine**  
Attending Physician  
Vanderbilt University Medical Center  
Nashville, TN



**Alison Moskowitz, MD**  
**Associate Professor of Medicine**  
Weill Cornell Medical College  
Associate Member  
Memorial Sloan Kettering Cancer Center  
New York, NY



**Eunice S. Wang, MD**  
**Professor of Oncology**  
Chief, Leukemia Service  
Roswell Park Comprehensive Cancer Center  
Buffalo, NY



**Yi Lin, MD, PhD**  
**Associate Professor of Medicine**  
Mayo Clinic College of Medicine and Science  
Mayo Clinic  
Rochester, MN



**David G Maloney, MD, PhD**  
**Professor, Cellular Immunotherapy**  
Medical Director  
Fred Hutchinson Cancer Center  
Seattle, WA



# Contact Information

For more information about the Gilead's Hematologic Malignancies program and to receive updates about future program cycles, visit:

[https://researchscholars.gilead.com/en/hematologic\\_malignancies\\_portal](https://researchscholars.gilead.com/en/hematologic_malignancies_portal)



Please subscribe to the portal in order to be informed about future program cycle timelines.



For general inquiries about the Research Scholars Program, please call or email:

**Gilead Sciences Research Scholars Program in Hematologic Malignancies**

**Attn:** Research Scholars Program Coordinator

**Email:** [gileadsciencesrsp@bcdme.com](mailto:gileadsciencesrsp@bcdme.com)